Market closed
Dare Bioscience/$DARE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Dare Bioscience
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Ticker
$DARE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
25
Website
Dare Bioscience Metrics
BasicAdvanced
$34M
Market cap
-
P/E ratio
-$0.91
EPS
1.39
Beta
-
Dividend rate
Price and volume
Market cap
$34M
Beta
1.39
52-week high
$7.56
52-week low
$3.05
Average daily volume
42K
Financial strength
Current ratio
1.428
Quick ratio
1.187
Long term debt to equity
200.067
Total debt to equity
218.339
Management effectiveness
Return on assets (TTM)
-71.42%
Return on equity (TTM)
30,070.81%
Valuation
Price to revenue (TTM)
11.183
Price to book
12.89
Price to tangible book (TTM)
12.89
Price to free cash flow (TTM)
-2.891
Growth
Earnings per share change (TTM)
-83.57%
3-year earnings per share growth (CAGR)
-54.18%
What the Analysts think about Dare Bioscience
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dare Bioscience stock.
Dare Bioscience Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Dare Bioscience Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Dare Bioscience News
AllArticlesVideos
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
GlobeNewsWire·1 day ago
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health
GlobeNewsWire·2 weeks ago
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dare Bioscience stock?
Dare Bioscience (DARE) has a market cap of $34M as of November 08, 2024.
What is the P/E ratio for Dare Bioscience stock?
The price to earnings (P/E) ratio for Dare Bioscience (DARE) stock is 0 as of November 08, 2024.
Does Dare Bioscience stock pay dividends?
No, Dare Bioscience (DARE) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Dare Bioscience dividend payment date?
Dare Bioscience (DARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Dare Bioscience?
Dare Bioscience (DARE) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.